<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="69">
  <stage>Registered</stage>
  <submitdate>25/07/2005</submitdate>
  <approvaldate>5/08/2005</approvaldate>
  <actrnumber>ACTRN12605000075684</actrnumber>
  <trial_identification>
    <studytitle>A randomized phase III study to evaluate the effectiveness of two different dosing regimens (high dose vs daily) of  Prednisone for boys with Duchenne muscular dystrophy in improving muscle strength and function and minimising side effects.</studytitle>
    <scientifictitle>A randomized phase III study to evaluate the effectiveness of two different dosing regimens (high dose vs daily) of  Prednisone for boys with Duchenne muscular dystrophy in improving muscle strength and function and minimising side effects.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Duchenne muscular dystrophy</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Comparison of daily low dose (0.75mg/kg/day) Prednisone to high dose Prednisone over 2 days (10mg/kg/week).</interventions>
    <comparator />
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Muscle strength</outcome>
      <timepoint>Measured at the start of the trial, and then 1,3,6,9 and 12 months after starting the prednisone</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Minimum side effects</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of Duchenne muscular dystrophy, ambulant, steroid na√Øve.</inclusivecriteria>
    <inclusiveminage>4</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>10</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Coordinating centre pharmacist will consult the site's randomization table</concealment>
    <sequence>Pre-generating a database of randomly permuted balanced blocks. Stratified to age (4 -7 years, 7-10 years)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/07/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>140</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Children's Hospital at Westmead</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Institute for Neuromuscular Research</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Cooperative International Neuromuscular Research Group</sponsorname>
      <sponsoraddress />
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To see which regimen of Prednisone - either a low daily dose or a high dose given on the two days of the weekend - gives the best positive effects (improvement in muscle strength) while minimising adverse effects (such as weight gain and behavioural changes)</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sian Rudge</name>
      <address>Clinical Sciences
The Children's Hospital at Westmead
Locked Bag 4001
Westmead NSW 2145</address>
      <phone>+61 2 98451229</phone>
      <fax>+61 2 98451317</fax>
      <email>sianr@chw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sian Rudge</name>
      <address>Clinical Sciences
The Children's Hospital at Westmead
Locked Bag 4001
Westmead NSW 2145</address>
      <phone>+61 2 98451229</phone>
      <fax>+61 2 98451317</fax>
      <email>sianr@chw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>